Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.
about
Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial.Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study.Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trailSafety and diagnostic accuracy of tumor biopsies in children with cancer.Informed consent in genomics and genetic research.Research biopsies in the context of early phase oncology studies: clinical and ethical considerations.Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey.Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trialsTargeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisitedMalignancies of the head and neck: the role for molecular targeted agents.The ethical use of mandatory research biopsiesAnalysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerationsEthics at phase 0: clarifying the issues.Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.Clinical biomarkers of angiogenesis inhibition.Are we HER-ting for innovation in neoadjuvant breast cancer trial design?Prospective clinical experience with research biopsies in breast cancer patients.Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?The clinical significance of radiologically detected silent pulmonary nodules in early breast cancerFeasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Research biopsies in phase I studies: views and perspectives of participants and investigators.Early oncology clinical trial design in the era of molecular-targeted agents.Biopsies: next-generation biospecimens for tailoring therapy.Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.Use of research biopsies in clinical trials: are risks and benefits adequately discussed?Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.Attitudes of patients with metastatic breast cancer toward research biopsies.Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).Attitudes of patients with metastatic cancer towards research biopsies.Genomic testing in cancer: patient knowledge, attitudes, and expectations.
P2860
Q30410657-3FCAC358-DB2C-47A5-93F6-AC2AAABC242BQ33162197-B13D68F7-79FF-454E-809A-54EDDEB28C7CQ33760585-6E070577-E60C-40C2-B25E-F43939D0894FQ34027888-7C1DA215-3E30-4B4C-A0FD-FA0FB782BEF4Q34085685-F61A7EA8-03CD-496F-8703-AA30C04DEACFQ34113504-23230F1E-BA5A-4380-A9EF-898201B6300DQ35202350-84B19EC0-28D7-4683-B2F7-F835FE39E16BQ35551797-902856B3-E82B-4799-869F-EB831642B3D3Q35569312-2C92823D-6CB7-4587-80B9-FD553F8C8371Q35584811-C565CC5B-816B-470F-93AB-3A1B3751C2BEQ36064901-E8E12D29-7B7B-41BE-81C0-08473571E647Q36446227-9AB28BB1-FF7C-437D-919D-3FFA53092155Q36493048-AD1D195A-57FB-4E30-86DC-08E76850093EQ36613969-7AE66ABB-3414-4ACD-A4CF-AAA8799ABBA6Q36670996-5947B0DC-FE7D-433B-9849-621B51012386Q36709551-B5CF14AA-4BDB-4FD7-961B-8972E7BCA61BQ36783493-6581924E-FD88-4DD0-A07B-2EED2234DE87Q36914483-6E3D7A63-FDFD-49B1-8FC0-3215BEC9DA39Q36984204-26B8DD35-6261-4FE2-A158-2C8685259860Q37030959-0F4C5610-1E70-4502-827E-D90E1D4392C7Q37111197-6275BBF6-F86D-4BE1-81A9-CEE9AA3CB960Q37139413-42A30B4B-A035-485E-BAFD-5EB10FD0D3BDQ37205521-D3960AF0-42E7-4438-833F-DDE55ACDC015Q37301389-B7E7EC69-F40C-4164-83F7-5DF6E962E240Q37316222-1D3FE89D-7CE9-409F-B061-2714DCD778CFQ37321913-A3675094-A4CD-42E4-AA70-034E7D87C150Q37429963-92687EDB-3F79-43D0-8DC5-7B0C7A5F934DQ37462283-2383C2C6-33F5-4006-9442-EA1A7E19F46FQ37687469-C09D7E62-5DC2-475B-9AD1-73F0B68FB75CQ37783623-5AA1D95D-1014-4C96-BBC1-8384C5B77614Q38116896-9E0BF4A9-1276-4BDE-AE5E-2F54EA8E1897Q41171803-7220A818-CD1E-48EA-B243-D09237C32F6BQ41264496-13CF9596-960D-420D-B4AD-F2973A2BA13EQ43679493-670E5665-2A11-4CEF-878B-3E2FB6AC233DQ43758141-B767B890-30A9-42AC-BCD2-BCFF788D30BEQ44100364-AC8F1498-838D-4B27-B492-732F65964970Q44962554-FC3ACF7D-0685-4ACB-ABF5-ACF727A3AC63Q47161072-FC560DAB-741D-4B6F-92EE-A7207E3493AEQ47309352-72A928A5-DE9E-4BE5-8470-FB1412F11723Q47755758-3CB3439A-80DC-456E-87F5-C200E66C0EDC
P2860
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Impact and perceptions of mand ...... ls of novel anticancer agents.
@ast
Impact and perceptions of mand ...... ls of novel anticancer agents.
@en
type
label
Impact and perceptions of mand ...... ls of novel anticancer agents.
@ast
Impact and perceptions of mand ...... ls of novel anticancer agents.
@en
prefLabel
Impact and perceptions of mand ...... ls of novel anticancer agents.
@ast
Impact and perceptions of mand ...... ls of novel anticancer agents.
@en
P2093
P356
P1476
Impact and perceptions of mand ...... ls of novel anticancer agents.
@en
P2093
Amit M Oza
Gregory R Pond
Lillian L Siu
Mark Agulnik
P304
P356
10.1200/JCO.2005.03.4496
P407
P577
2006-10-01T00:00:00Z